Bruker Corporation reported third quarter 2024 revenues of $864.4 million, an increase of 16.4% year-over-year. Organic revenue growth was 3.1%, with constant-exchange rate (CER) revenue growth reaching 15.7%.
Despite revenue growth, non-GAAP operating income decreased by 12.9% to $129.1 million, resulting in a non-GAAP operating margin of 14.9%, down 510 basis points from the prior year. Non-GAAP diluted earnings per share (EPS) were $0.60, a decrease of 18.9% compared to $0.74 in Q3 2023.
The company revised its full-year 2024 guidance, now expecting revenues between $3.34 billion and $3.37 billion, and non-GAAP EPS in the range of $2.36 to $2.41. This revised outlook reflects delays in biopharma and China market recoveries.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.